Global Biotechnology Company Licenses WinNonlin AutoPilot

MOUNTAIN VIEW, Calif., July 31, 2008 (PRIME NEWSWIRE) -- Pharsight Corporation
(Nasdaq:PHST), a leading provider of software, strategic consulting, and
regulatory services for optimizing clinical drug development, today announced
that a global biotechnology company has purchased WinNonlin AutoPilot(tm) to use
in conjunction with its licenses of WinNonlin and Pharsight Knowledgebase
Server(tm) (PKS(tm)). The customer is the seventh company to adopt WinNonlin
AutoPilot.

WinNonlin AutoPilot is configurable software that pre-clinical and clinical
research scientists can use to automate common or repetitive tasks during
clinical pharmacokinetic (PK) analysis, thus saving time in the generation of
report-ready tables, charts, listings, and graphs. Using WinNonlin AutoPilot,
companies can increase their productivity while improving the quality and
consistency of analyses and reports. The customer already benefits from the use
of PKS to store study data and results in a single, secure, accessible
repository for PK/PD data. Adding WinNonlin AutoPilot moves the firm toward
Pharsight's best practices paradigm for integrated PK/PD analysis, data
management and reporting.

"The purpose of AutoPilot is to increase efficiency in the generation of
standardized tables, figures, and listings for regulatory analysis and
reporting, while improving scientific productivity by reducing non-research
related activities such as data acquisition and report formatting," said Shawn
O'Connor, chairman, CEO, and president of Pharsight.

About WinNonlin AutoPilot

AutoPilot orchestrates PK analyses by selecting input data from a user's local
file system or Pharsight Knowledgebase Server ("PKS"), and then directs
WinNonlin to perform analyses and produce report quality tables, figures, and
text output (e.g., in Microsoft(r) Excel(tm), SigmaPlot(r), and Microsoft
Word(tm)) for regulatory submissions and interim reports. Formatted PK analyses
outputs must reflect the requirements and SOPs of each research organization,
and WinNonlin AutoPilot provides a user interface that allows extensive
configuration of formatting and business rules to enable clear communication of
standards and immediate use across the organization. PK analyses that can be
automated include noncompartmental analysis for different study designs and
inferential statistics (e.g., bioequivalence testing), as well as comparisons
between analytes, dose routes or other conditions. Used in conjunction with PKS
and PKS Reporter(tm), WinNonlin AutoPilot provides standardized, regulatory
compliant, secure and automatic generation of routine analyses and reports. Used
independently of PKS and PKS Reporter, WinNonlin AutoPilot can provide
significant return on investment through productivity gains and quality
improvements in PK analysis and reporting.

About PKS

The Pharsight Knowledgebase Server (PKS) is a high-productivity,
regulatory-compliant enterprise data management system. PKS is now installed in
22 major pharmaceutical and biotechnology companies and also at FDA in
connection with an extensive Pharsight-FDA Cooperative Research and Development
Agreement. PKS enables pharmaceutical and biopharmaceutical companies to better
manage and control preclinical and clinical kinetic and dynamic data and
analyses. Companies use PKS to build pharmacokinetic and pharmacodynamic (PK/PD)
data management architecture compliant with FDA regulation 21 CFR Part 11, which
has set new standards for computer system validation and usage. The PKS software
is designed to complement Pharsight's modeling and simulation technology for
computer-based drug-disease modeling and clinical trial simulation. PKS supports
analysis in leading tools such as WinNonlin, NONMEM(r), and SAS(r) as well as
connectivity to LIMS such as Watson LIMS.

About Pharsight Corporation

Pharsight Corporation develops and markets integrated products and services that
enable pharmaceutical and biotechnology companies to achieve significant and
enduring improvements in the development and use of therapeutic products. The
company's goal is to help customers reduce the time, cost and risk of drug
development, as well as optimize the post-approval marketing and use of
pharmaceutical products.

Pharsight's approach enhances the fundamental element of drug development
success: strong decision-making. By adopting the Pharsight approach, customers
acquire a new decision-making process with the potential to systematically
improve every level and phase of their business and scientific processes.
Pharsight Corporation is headquartered in Mountain View, California. Information
about Pharsight is available at http://www.pharsight.com.

Forward Looking Statements

The statements in this press release related to the performance of Pharsight
products are forward looking statements. Forward-looking statements are
inherently speculative, and actual results may differ materially from
Pharsight's expectations due to a variety of factors, including: changes in FDA
regulations may affect the demand for the product; and customers may not
perceive the benefits of the product to be the same as Pharsight believes them
to be. Other risk factors relating to Pharsight are disclosed in the company's
most recent Form 10-Q filed with the Securities and Exchange Commission on June
30, 2008. All forward-looking statements are based on information available to
the company on the date hereof, and the company assumes no obligation to update
such statements.

Registered Trademarks and Trademarks

Pharsight, Pharsight Knowledgebase Server, PKS, WinNonlin, WinNonlin AutoPilot,
and IVIVC Toolkit for WinNonlin are trademarks or registered trademarks of
Pharsight Corporation. NONMEM, Word, Excel, Watson, and SAS are trademarks or
registered trademarks of their respective holders.

-0-
CONTACT: EVC Group
Investors
Dahlia Bailey
Douglas Sherk
415-896-6820
Media
Steve DiMattia
646-201-5445